Preliminary data indicate a protective effect on the development of duodenal polyps by coxib
treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for
1 year would stop or reverse the development of premalignant adenomatous lesions in the
duodenal mucosa of FAP patients.